Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

Develops treatments for neurodegenerative diseases

About Amylyx Pharmaceuticals

Simplify's Rating
Why Amylyx Pharmaceuticals is rated
C
Rated C on Competitive Edge
Rated D+ on Growth Potential
Rated B on Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2013

Overview

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in patients with early dementia related to Alzheimer's. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Gubra enhances treatment efficacy for neurodegenerative diseases.
  • Acquisition of avexitide diversifies Amylyx's therapeutic portfolio.
  • HELIOS trial shows AMX0035's potential for treating Wolfram syndrome.

What critics are saying

  • Departure of key personnel may disrupt clinical development.
  • Failure of PHOENIX trial impacts investor confidence.
  • Low stock offering price suggests potential financial instability.

What makes Amylyx Pharmaceuticals unique

  • Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's.
  • AMX0035 is a promising drug for ALS and Alzheimer's treatment.
  • Amylyx engages in community awareness campaigns for neurodegenerative diseases.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$695.5M

Above

Industry Average

Funded Over

7 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Remote Work Options

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

↓ -6%

1 year growth

↓ -14%

2 year growth

↑ 6%
Business Wire
Feb 18th, 2025
Nura Bio Expands Leadership Team with C-Suite Appointments

Lahar Mehta, M.D. Lahar Mehta, M.D., joins Nura Bio from Amylyx Pharmaceuticals, where he was Senior Vice President/Head, Global Clinical Development, leading clinical development and clinical pharmacology activities across several indications including amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and Wolfram syndrome.

ETF Daily News
Jan 13th, 2025
Amylyx Pharmaceuticals Enters Underwriting Agreement for Public Offering

On January 10, 2025, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced its entry into an underwriting agreement with Leerink Partners LLC for the issuance and sale of 17,142,857 shares of its common stock at a price of $3.50 per share.

Business Wire
Jan 11th, 2025
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 s

CityBiz
Jan 6th, 2025
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

Amylyx Pharmaceuticals appoints Dan Monahan as Chief Commercial Officer.

TipRanks
Dec 30th, 2024
Amylyx Partners with Gubra for GLP-1 Antagonist

Amylyx partners with Gubra for GLP-1 antagonist.

Recently Posted Jobs

Sign up to get curated job recommendations

Amylyx Pharmaceuticals is Hiring for 6 Jobs on Simplify!

Find jobs on Simplify and start your career today

đź’ˇ
We update Amylyx Pharmaceuticals's jobs every few hours, so check again soon! Browse all jobs →